Octave Bioscience Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 38
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $2.5M
Latest Deal Amount
  • Investors
  • 9

Octave Bioscience General Information

Description

Developer of a care management platform designed to improve patient outcomes. The company's platform focuses on neurodegenerative diseases starting with multiple sclerosis and combines quantitative measurements with analytics tools to evaluate neurodegenerative disease pathways, enabling neurologists to improve patient management decisions and create beneficial outcomes at low costs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Enterprise Systems (Healthcare)
Primary Office
  • 1440 Obrien Drive
  • Suite B
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

Octave Bioscience Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Octave Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 11-Oct-2021 $2.5M 0000 00000 Completed Generating Revenue
3. Later Stage VC (Series B) 29-Oct-2020 0000 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series A) 12-Jul-2018 $14M $16.5M 0000 Completed Generating Revenue
1. Seed Round 13-Sep-2017 $2.5M $2.5M 00.000 Completed Generating Revenue
To view Octave Bioscience’s complete valuation and funding history, request access »

Octave Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 2,500,000 $0.000100 8% $1 $1 1x $1 10.7%
To view Octave Bioscience’s complete cap table history, request access »

Octave Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a care management platform designed to improve patient outcomes. The company's platform focuses on neurodeg
Decision/Risk Analysis
Menlo Park, CA
38 As of 2021
0000
0000 0000-00-00
00000000000 0000

00000 00

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqu
0000000000000 00000000
Helsinki, Finland
00 As of 0000
00.000
000000&0 00.000

000000 0

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labo
0000000000000 00000000
Chicago, IL
0000 As of 0000
00.000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Octave Bioscience Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Noona Healthcare Formerly VC-backed Helsinki, Finland 00 00.000 000000&0 00.000
000000 0000 Venture Capital-Backed Chicago, IL 0000 00.000 00000000
000000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
0000000 Venture Capital-Backed San Francisco, CA 00 0000 00000000000 0000
000000000 000000 0 Private Equity-Backed Irving, TX 000 0000000 0000
You’re viewing 5 of 24 competitors. Get the full list »

Octave Bioscience Patents

Octave Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3021036-A1 Methods for assessment of multiple sclerosis activity Pending 15-Apr-2016 0000000000
EP-3443125-A4 Methods for assessment of multiple sclerosis activity Pending 15-Apr-2016 0000000000 0
EP-3443125-A1 Methods for assessment of multiple sclerosis activity Pending 15-Apr-2016 0000000000
US-20190127798-A1 Methods for assessment of multiple sclerosis activity Pending 15-Apr-2016 C12Q1/6883

Octave Bioscience Executive Team (7)

Name Title Board Seat Contact Info
William Hagstrom Co-Founder, Chief Executive Officer & Board Member
Melinda Thomas Co-Founder & Chief Operating Officer
Erwan Rivet Chief Technology Officer
Mike Edgeworth MD Chief Population Health Officer
Michael Becich Platform Insights Lead
You’re viewing 5 of 7 executive team members. Get the full list »

Octave Bioscience Board Members (7)

Name Representing Role Since
A. Grant Heidrich III Self Board Member 000 0000
Andrea Jackson Self Board Member 000 0000
Brook Byers Ph.D Kleiner Perkins Board Member 000 0000
George Scangos Ph.D Self Board Member 000 0000
Michael Pellini MD Section 32 Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Octave Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Octave Bioscience Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Merck Global Health Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Northpond Ventures Venture Capital Minority 000 0000 000000 0
Echo Health Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »